RaQualia Pharma Inc.
Notice of Receipt of Milestone Payment Following Start of Phase II Clinical Trial for a Novel Sodium Channel Blocker
A milestone payment of 200 million yen is scheduled to be received under the license agreement with Hisamitsu Pharmaceutical. The payment is triggered by the start of a Phase II clinical trial and will be recorded as operating revenue in Q4 of the fiscal year ending December 2026. The impact has already been factored into the earnings forecast and no additional earnings revision is planned at this time.
Key Figures
- Milestone payment: 200 million yen
- Recognition timing: Q4 of the fiscal year ending December 2026
- Clinical progress: Start of Phase II clinical trial (related to agreement with Hisamitsu Pharmaceutical)
AI要約
Key Points
RaQualia Pharma Inc. announced that, following the start of a Phase II clinical trial for a transdermal product containing a novel sodium channel blocker licensed to Hisamitsu Pharmaceutical, it expects to receive a milestone payment of 200 million yen. This milestone will be recognized as operating revenue in Q4 of the fiscal year ending December 2026, and its effect on consolidated results has already been incorporated.
Business Impact and Outlook
No additional earnings revisions are planned at this time. Through strengthened collaboration with Hisamitsu Pharmaceutical, the company aims to enhance corporate value by providing treatment options in the pain-related field. Depending on clinical development progress, this may affect future development and commercialization prospects and associated revenues.
RaQualia Pharma Inc.
Company overview · Stock price · Financial data · All IR
